A 68-year-old woman with ER+/HER2- early breast cancer (pT2 N0, grade 2) is assessed using the CTS5 (Clinical Treatment Score post-5 years) tool

Question

A 68-year-old woman with ER+/HER2- early breast cancer (pT2 N0, grade 2) is assessed using the CTS5 (Clinical Treatment Score post-5 years) tool after completing 5 years of tamoxifen. Her CTS5 score predicts a high late recurrence risk (>10% at 5-10 years). What does this tool specifically assess?

Accepted Answer

Risk of late distant recurrence (years 5-10) to guide extended endocrine therapy decisions

Answer

Chemotherapy benefit as the preferred next management strategy in this patient

Answer

Risk of early recurrence (0-5 years) as the preferred next management strategy

Answer

Surgical margin adequacy as the preferred next management strategy in this patient

Answer

HER2 status prediction as the preferred next management strategy in this patient

Breast Cancer — SCE Medical Oncology MCQ

A 68-year-old woman with ER+/HER2- early breast cancer (pT2 N0, grade 2) is assessed using the CTS5 (Clinical Treatment Score post-5 years) tool after completing 5 years of tamoxifen. Her CTS5 score predicts a high late recurrence risk (>10% at 5-10 years). What does this tool specifically assess?